Michael A Bookman

Summary

Affiliation: University of Arizona
Country: USA

Publications

  1. doi request reprint First-line chemotherapy in epithelial ovarian cancer
    Michael A Bookman
    University of Arizona Cancer Center, Tucson, Arizona, USA
    Clin Obstet Gynecol 55:96-113. 2012
  2. ncbi request reprint Trials with impact on clinical management: first line
    Michael A Bookman
    Arizona Cancer Center, 1515 N Campbell Avenue, Tucson, AZ 85724 5024, USA
    Int J Gynecol Cancer 19:S55-62. 2009
  3. doi request reprint The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer
    M A Bookman
    Arizona Cancer Center, Tucson, AZ 85724 5024, USA
    Ann Oncol 21:vii211-17. 2010
  4. doi request reprint Update of randomized trials in first-line treatment
    Michael A Bookman
    Arizona Cancer Center, 1515 N Campbell Avenue, Tucson, AZ 85724 5024, USA
    Ann Oncol 22:viii52-viii60. 2011
  5. pmc Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study
    Robert A Burger
    Robert A Burger, Fox Chase Cancer Center, Philadelphia, PA Mark F Brady, GOG Statistical and Data Center, Buffalo, NY Michael A Bookman, Arizona Cancer Center, Tucson, AZ Bradley J Monk, University of California at Irvine, Orange, CA Joan L Walker, University of Oklahoma, Oklahoma City, OK Howard D Homesley, Wake Forest University Medical Center, Winston Salem, NC Jeffrey Fowler, Ohio State University, Columbus, OH Benjamin E Greer, University of Washington Medical Center, Seattle, WA Matthew Boente, Minnesota Oncology Hematology, Minneapolis, MN Gini F Fleming, University of Chicago, Chicago, IL Peter C Lim, Center of Hope at Renown Regional Medical Center, Reno, NV Stephen C Rubin, University of Pennsylvania Cancer Center, Philadelphia, PA Noriyuki Katsumata, Saitama Medical University International Medical Center GOG Japan, Saitama, Japan and Sharon X Liang, North Shore University Hospital, Manhasset, USA
    J Clin Oncol 32:1210-7. 2014

Detail Information

Publications5

  1. doi request reprint First-line chemotherapy in epithelial ovarian cancer
    Michael A Bookman
    University of Arizona Cancer Center, Tucson, Arizona, USA
    Clin Obstet Gynecol 55:96-113. 2012
    ..Encouraging data have emerged using antiangiogenic agents, but with questions regarding optimal timing and patient selection. The use of 3-drug combinations or maintenance chemotherapy is not supported...
  2. ncbi request reprint Trials with impact on clinical management: first line
    Michael A Bookman
    Arizona Cancer Center, 1515 N Campbell Avenue, Tucson, AZ 85724 5024, USA
    Int J Gynecol Cancer 19:S55-62. 2009
    ..Emerging data from these trials need to be interpreted within an evolving paradigm of cancer biology, disease management, and availability of clinical resources...
  3. doi request reprint The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer
    M A Bookman
    Arizona Cancer Center, Tucson, AZ 85724 5024, USA
    Ann Oncol 21:vii211-17. 2010
    ..Emerging biological paradigms will hopefully contribute to individualized treatment options in the future...
  4. doi request reprint Update of randomized trials in first-line treatment
    Michael A Bookman
    Arizona Cancer Center, 1515 N Campbell Avenue, Tucson, AZ 85724 5024, USA
    Ann Oncol 22:viii52-viii60. 2011
    ..Ongoing and planned trials will evaluate the inhibition of DNA repair and tailored treatment in accordance with tumor molecular profiles...
  5. pmc Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study
    Robert A Burger
    Robert A Burger, Fox Chase Cancer Center, Philadelphia, PA Mark F Brady, GOG Statistical and Data Center, Buffalo, NY Michael A Bookman, Arizona Cancer Center, Tucson, AZ Bradley J Monk, University of California at Irvine, Orange, CA Joan L Walker, University of Oklahoma, Oklahoma City, OK Howard D Homesley, Wake Forest University Medical Center, Winston Salem, NC Jeffrey Fowler, Ohio State University, Columbus, OH Benjamin E Greer, University of Washington Medical Center, Seattle, WA Matthew Boente, Minnesota Oncology Hematology, Minneapolis, MN Gini F Fleming, University of Chicago, Chicago, IL Peter C Lim, Center of Hope at Renown Regional Medical Center, Reno, NV Stephen C Rubin, University of Pennsylvania Cancer Center, Philadelphia, PA Noriyuki Katsumata, Saitama Medical University International Medical Center GOG Japan, Saitama, Japan and Sharon X Liang, North Shore University Hospital, Manhasset, USA
    J Clin Oncol 32:1210-7. 2014
    ..To evaluate risk factors for GI adverse events (AEs) within a phase III trial of bevacizumab in first-line ovarian cancer therapy...